Market Overview:
The global ischemic heart disease drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of ischemic heart diseases, rising geriatric population, and technological advancements in the field of drug discovery and development. Based on type, the global ischemic heart disease drugs market can be segmented into angina pectoris, myocardial infarction (MI), and other types. Angina pectoris accounted for the largest share of this market in 2017 owing to its high prevalence rate. Based on application, this market can be divided into anti-dyslipidemic drugs, calcium channel blockers (CCBs), beta-blockers (BBs), ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), vasodilators, and antithrombotic agents. Anti-dyslipidemic drugs held the largest share of this market in 2017 due to their widespread use for treating dyslipidemia associated with various cardiovascular diseases such as MI and stroke.
Product Definition:
Ischemic heart disease drugs are used to prevent and treat ischemic heart disease. Ischemic heart disease is a condition in which the blood supply to the heart muscle is reduced, leading to chest pain (angina) and other symptoms. These drugs include statins, beta blockers, and ACE inhibitors. They work by decreasing the risk of a heart attack or stroke, improving blood flow to the heart muscle, and reducing symptoms of angina.
Angina Pectoris:
The angina pectoris is a clinical indication characterized by transient myocardial ischemia without infarction and typically follows exertional heart attacks. Angina pectoris was first recognized as a distinct clinical entity in 1747 by the French physician, Charles-Édouard Brown-Séquard who observed it in patients following his cardiac surgeries. The condition was also known as "the heart's ache" or "the pain of unknown origin".
Myocardial Infarction:
Myocardial infarction is a heart attack. It is also called coronary thrombosis or myocardial cell damage due to lack of blood flow in the myocardium, which covers the muscle of heart. Myocardium means “muscle meat” and/or “cardiac muscle”.
Application Insights:
The anti-dyslipidemic drugs segment dominated the global ischemic heart disease drugs market in 2017. This can be attributed to the increasing prevalence of dyslipidemia and its associated complications, such as cardiovascular diseases (CVDs) and stroke. According to a study published by National Center for Biotechnology Information, around 1 in 3 deaths globally are caused by CVDs. Furthermore, according to WHO, around 30 million people die from CVDs every year worldwide. Thus, rising incidences of these disorders create opportunities for pharmaceutical companies developing new products with better therapeutic benefits at lower costs.
Angina pectoris is expected to be the fastest growing application segment due largely to increased incidence of angina pectoris among both genders above 40 years old and physical exertion during exercise or sports activities which may result in myocardial infarction if proper medical treatment is not taken immediately after onset of symptoms i.e.
Regional Analysis:
North America dominated the global market in 2017. High prevalence of ischemic heart disease, favorable reimbursement scenario, and increasing healthcare expenditure are some of the key factors contributing to its growth. Moreover, presence of major players such as Pfizer Inc.; Merck & Co., Inc.; and Sanofi are also expected to boost revenue generation in this region.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising geriatric population base coupled with an increase in lifestyle-associated diseases like diabetes that may lead to cardiac disorders. In addition, growing awareness about early diagnosis among patients will further drive regional demand during the forecast period. Increasing disposable income levels will also contribute toward market development due to availability of better treatment options for Ischemic Heart Disease (IHD) at affordable prices compared with developed regions such as North America and Europe (USD X).
Growth Factors:
- Increasing incidence of ischemic heart disease (IHD) due to changing lifestyle and dietary habits.
- Growing awareness about the symptoms and risk factors of IHD among people.
- Rising demand for better and more effective treatment options for IHD patients.
- Technological advancements in the field of ischemic heart disease drugs development and commercialization.
Scope Of The Report
Report Attributes
Report Details
Report Title
Ischemic Heart Disease Drugs Market Research Report
By Type
Angina Pectoris, Myocardial Infarction
By Application
Anti-dyslipidemic Drugs, Calcium Channel Blockers, Beta-blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents
By Companies
AstraZeneca, Actelion, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Baxter, Eli Lilly and Company, Novartis, Pfizer, Sanofi, AstraZeneca
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
139
Number of Tables & Figures
98
Customization Available
Yes, the report can be customized as per your need.
Global Ischemic Heart Disease Drugs Market Report Segments:
The global Ischemic Heart Disease Drugs market is segmented on the basis of:
Types
Angina Pectoris, Myocardial Infarction
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Anti-dyslipidemic Drugs, Calcium Channel Blockers, Beta-blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Actelion
- Bayer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Baxter
- Eli Lilly and Company
- Novartis
- Pfizer
- Sanofi
- AstraZeneca
Highlights of The Ischemic Heart Disease Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Angina Pectoris
- Myocardial Infarction
- By Application:
- Anti-dyslipidemic Drugs
- Calcium Channel Blockers
- Beta-blockers
- ACE Inhibitors
- ARBs
- Vasodilators
- Antithrombotic Agents
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ischemic Heart Disease Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ischemic heart disease drugs are medications that help to improve the blood flow to the heart. These medications can be used in combination with other treatments, such as lifestyle changes and exercise, to help prevent or reduce the severity of ischemic heart disease.
Some of the major companies in the ischemic heart disease drugs market are AstraZeneca, Actelion, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Baxter, Eli Lilly and Company, Novartis, Pfizer, Sanofi, AstraZeneca.
The ischemic heart disease drugs market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ischemic Heart Disease Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Ischemic Heart Disease Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Ischemic Heart Disease Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Ischemic Heart Disease Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Ischemic Heart Disease Drugs Market Size & Forecast, 2020-2028
4.5.1 Ischemic Heart Disease Drugs Market Size and Y-o-Y Growth
4.5.2 Ischemic Heart Disease Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Angina Pectoris
5.2.2 Myocardial Infarction
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Anti-dyslipidemic Drugs
6.2.2 Calcium Channel Blockers
6.2.3 Beta-blockers
6.2.4 ACE Inhibitors
6.2.5 ARBs
6.2.6 Vasodilators
6.2.7 Antithrombotic Agents
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ischemic Heart Disease Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ischemic Heart Disease Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Angina Pectoris
9.6.2 Myocardial Infarction
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Anti-dyslipidemic Drugs
9.10.2 Calcium Channel Blockers
9.10.3 Beta-blockers
9.10.4 ACE Inhibitors
9.10.5 ARBs
9.10.6 Vasodilators
9.10.7 Antithrombotic Agents
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Angina Pectoris
10.6.2 Myocardial Infarction
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Anti-dyslipidemic Drugs
10.10.2 Calcium Channel Blockers
10.10.3 Beta-blockers
10.10.4 ACE Inhibitors
10.10.5 ARBs
10.10.6 Vasodilators
10.10.7 Antithrombotic Agents
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Angina Pectoris
11.6.2 Myocardial Infarction
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Anti-dyslipidemic Drugs
11.10.2 Calcium Channel Blockers
11.10.3 Beta-blockers
11.10.4 ACE Inhibitors
11.10.5 ARBs
11.10.6 Vasodilators
11.10.7 Antithrombotic Agents
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Angina Pectoris
12.6.2 Myocardial Infarction
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Anti-dyslipidemic Drugs
12.10.2 Calcium Channel Blockers
12.10.3 Beta-blockers
12.10.4 ACE Inhibitors
12.10.5 ARBs
12.10.6 Vasodilators
12.10.7 Antithrombotic Agents
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Angina Pectoris
13.6.2 Myocardial Infarction
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Anti-dyslipidemic Drugs
13.10.2 Calcium Channel Blockers
13.10.3 Beta-blockers
13.10.4 ACE Inhibitors
13.10.5 ARBs
13.10.6 Vasodilators
13.10.7 Antithrombotic Agents
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ischemic Heart Disease Drugs Market: Competitive Dashboard
14.2 Global Ischemic Heart Disease Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Actelion
14.3.3 Bayer
14.3.4 Boehringer Ingelheim
14.3.5 Bristol-Myers Squibb
14.3.6 Baxter
14.3.7 Eli Lilly and Company
14.3.8 Novartis
14.3.9 Pfizer
14.3.10 Sanofi
14.3.11 AstraZeneca
